These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1441 related items for PubMed ID: 26873684

  • 21. Subcutaneous Implantable Cardioverter Defibrillator Lead Repositioning for Preventing Inappropriate Shocks Due to Myopotential Oversensing in a Post-Fulminant Myocarditis Patient.
    Sasaki T, Nakamura K, Naito S.
    Int Heart J; 2019 Mar 20; 60(2):466-469. PubMed ID: 30745542
    [Abstract] [Full Text] [Related]

  • 22. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy.
    O'Mahony C, Tome-Esteban M, Lambiase PD, Pantazis A, Dickie S, McKenna WJ, Elliott PM.
    Heart; 2013 Apr 20; 99(8):534-41. PubMed ID: 23339826
    [Abstract] [Full Text] [Related]

  • 23. Low Prevalence of Inappropriate Shocks in Patients With Inherited Arrhythmia Syndromes With the Subcutaneous Implantable Defibrillator Single Center Experience and Long-Term Follow-Up.
    Rudic B, Tülümen E, Berlin V, Röger S, Stach K, Liebe V, El-Battrawy I, Dösch C, Papavassiliu T, Akin I, Borggrefe M, Kuschyk J.
    J Am Heart Assoc; 2017 Oct 17; 6(10):. PubMed ID: 29042423
    [Abstract] [Full Text] [Related]

  • 24. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy.
    Lin G, Nishimura RA, Gersh BJ, Phil D, Ommen SR, Ackerman MJ, Brady PA.
    Heart; 2009 May 17; 95(9):709-14. PubMed ID: 19282314
    [Abstract] [Full Text] [Related]

  • 25. Intraoperative Defibrillation Testing of Subcutaneous Implantable Cardioverter-Defibrillator Systems-A Simple Issue?
    Frommeyer G, Zumhagen S, Dechering DG, Larbig R, Bettin M, Löher A, Köbe J, Reinke F, Eckardt L.
    J Am Heart Assoc; 2016 Mar 15; 5(3):e003181. PubMed ID: 27068637
    [Abstract] [Full Text] [Related]

  • 26. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
    Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, Estes NA, Shannon KM, Ashley EA, Day SM, Pacileo G, Formisano F, Devoto E, Anastasakis A, Bos JM, Woo A, Autore C, Pass RH, Boriani G, Garberich RF, Almquist AK, Russell MW, Boni L, Berger S, Maron MS, Link MS.
    J Am Coll Cardiol; 2013 Apr 09; 61(14):1527-35. PubMed ID: 23500286
    [Abstract] [Full Text] [Related]

  • 27. The ICD for primary prevention in patients with inherited cardiac diseases: indications, use, and outcome: a comparison with secondary prevention.
    Olde Nordkamp LR, Wilde AA, Tijssen JG, Knops RE, van Dessel PF, de Groot JR.
    Circ Arrhythm Electrophysiol; 2013 Feb 09; 6(1):91-100. PubMed ID: 23275262
    [Abstract] [Full Text] [Related]

  • 28. Safety and Efficacy of Subcutaneous Cardioverter Defibrillator in Patients at High Risk of Sudden Cardiac Death　- Primary Japanese Experience.
    Sasaki S, Tomita H, Tsurugi T, Ishida Y, Shoji Y, Nishizaki K, Kinjo T, Endo T, Nishizaki F, Hanada K, Sasaki K, Horiuchi D, Kimura M, Higuma T, Okamatsu H, Tanaka Y, Koyama J, Okumura K.
    Circ J; 2018 May 25; 82(6):1546-1551. PubMed ID: 29643282
    [Abstract] [Full Text] [Related]

  • 29. Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy-Are there predictors of appropriate therapy?
    Weissler-Snir A, Dorian P, Rakowski H, Care M, Spears D.
    Heart Rhythm; 2021 Jan 25; 18(1):63-70. PubMed ID: 32800967
    [Abstract] [Full Text] [Related]

  • 30. Hypertrophic Cardiomyopathy and Implantable Defibrillators in Sweden: Inappropriate Shocks and Complications Requiring Surgery.
    Magnusson P, Gadler F, Liv P, Mörner S.
    J Cardiovasc Electrophysiol; 2015 Oct 25; 26(10):1088-94. PubMed ID: 26178879
    [Abstract] [Full Text] [Related]

  • 31. Which patients are not suitable for a subcutaneous ICD: incidence and predictors of failed QRS-T-wave morphology screening.
    Olde Nordkamp LRA, Warnaars JLF, Kooiman KM, de Groot JR, Rosenmöller BRAM, Wilde AAM, Knops RE.
    J Cardiovasc Electrophysiol; 2014 May 25; 25(5):494-499. PubMed ID: 24320684
    [Abstract] [Full Text] [Related]

  • 32. Implantable cardioverter-defibrillators in patients with hypertrophic cardiomyopathy -- dilemmas and difficulties.
    Przybylski A, Małecka L, Pytkowski M, Chojnowska L, Lewandowski M, Sterliński M, Maciag A, Ruzyłło W, Szwed H.
    Kardiol Pol; 2005 Oct 25; 63(4):391-7; discussion 398. PubMed ID: 16273479
    [Abstract] [Full Text] [Related]

  • 33. Implantable cardioverter defibrillator therapy in paediatric practice: a single-centre UK experience with focus on subcutaneous defibrillation.
    Griksaitis MJ, Rosengarten JA, Gnanapragasam JP, Haw MP, Morgan JM.
    Europace; 2013 Apr 25; 15(4):523-30. PubMed ID: 23333943
    [Abstract] [Full Text] [Related]

  • 34. The T-peak-to-T-end interval: a novel ECG marker for ventricular arrhythmia and appropriate ICD therapy in patients with hypertrophic cardiomyopathy.
    Dinshaw L, Münch J, Dickow J, Lezius S, Willems S, Hoffmann BA, Patten M.
    Clin Res Cardiol; 2018 Feb 25; 107(2):130-137. PubMed ID: 28965260
    [Abstract] [Full Text] [Related]

  • 35. Recent developments in the subcutaneous ICD.
    Willcox ME, Prutkin JM, Bardy GH.
    Trends Cardiovasc Med; 2016 Aug 25; 26(6):526-35. PubMed ID: 27079889
    [Abstract] [Full Text] [Related]

  • 36. Oversensing issues leading to device extraction: When subcutaneous implantable cardioverter-defibrillator reached a dead-end.
    Noel A, Ploux S, Bulliard S, Strik M, Haeberlin A, Welte N, Marchand H, Klotz N, Ritter P, Haïssaguerre M, Bordachar P.
    Heart Rhythm; 2020 Jan 25; 17(1):66-74. PubMed ID: 31295585
    [Abstract] [Full Text] [Related]

  • 37. Ventricular Tachyarrhythmias in Patients With Hypertrophic Cardiomyopathy and Defibrillators: Triggers, Treatment, and Implications.
    Link MS, Bockstall K, Weinstock J, Alsheikh-Ali AA, Semsarian C, Estes NAM, Spirito P, Haas TS, Rowin EJ, Maron MS, Maron BJ.
    J Cardiovasc Electrophysiol; 2017 May 25; 28(5):531-537. PubMed ID: 28240435
    [Abstract] [Full Text] [Related]

  • 38. Clinical impact of defibrillation testing at the time of implantable cardioverter-defibrillator insertion.
    Hadid C, Atienza F, Strasberg B, Arenal Á, Codner P, González-Torrecilla E, Datino T, Percal T, Almendral J, Ortiz M, Martins R, Martinez-Alzamora N, Fernandez Aviles F.
    Cardiol J; 2015 May 25; 22(3):253-9. PubMed ID: 25179316
    [Abstract] [Full Text] [Related]

  • 39. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].
    Marín F, Gimeno JR, Payá E, García-Alberola A, Pérez-Alvarez L, Fernández X, de la Morena G, Sogorb F, Castro-Beiras A, Valdés M, Martínez JG, Monserrat L.
    Rev Esp Cardiol; 2006 Jun 25; 59(6):537-44. PubMed ID: 16790196
    [Abstract] [Full Text] [Related]

  • 40. Long-term follow-up in patients with arrhythmogenic right ventricular cardiomyopathy.
    Li CH, Lin YJ, Huang JL, Wu TJ, Cheng CC, Lin WS, Tuan TC, Chang SL, Lo LW, Hu YF, Chao TF, Chung FP, Tsai CF, Tsao HM, Chen SA.
    J Cardiovasc Electrophysiol; 2012 Jul 25; 23(7):750-6. PubMed ID: 22353378
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 73.